Previous 10 | Next 10 |
Enzo Biochem ( NYSE: ENZ ) appoints Patricia Eckert as interim CFO, succeeding David Bench, who is departing the company effective November 14, 2022 to pursue a new opportunity. Prior to her nearly five years in various finance roles with Enzo, Ms. Eck...
NEW YORK, NY, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the appointment of Patricia Eckert, CPA, as interim Chief Financial Officer (CFO). Ms. E...
Enzo Biochem press release ( NYSE: ENZ ): Q4 Non-GAAP EPS of -$0.17. Revenue of $20.28M (-18.2% Y/Y). For further details see: Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M
- Enzo Life Sciences reports revenue of $32.6 million and 8% growth in FY 2022, net of FX - Company successfully launched AMPIVIEW™ gene expression platform powered by LoopRNA™ ISH technology - Continues to engage with previously announced investment bank t...
Conference Call and Webcast Scheduled for October 1 4 , 202 2 , 8 : 3 0 a m ET NEW YORK, NY, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a l...
100,000 square foot facility to support company plans for growth in clinical laboratory services, drug development services and product innovations Launch event to feature updates on Enzo plans for business growth and perspectives on prospects for the Long Island business communit...
NEW YORK, NY, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the launch of the AMPIVIEW™ line, a breakthrough RNA gene expression platform powered ...
NEW YORK, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced today that its full-service clinical laboratory will begin accepting specimens for monkeypox (MPX) t...
On June 9, Enzo Biochem announced a new strategic review that may finally lead to the sale of the long-mismanaged company. Since late 2021, positive changes have taken place - long-time CEO Rabbani was replaced with an independent CEO, an experienced activist was appointed to the Boar...
Enzo Biochem, Inc. (ENZ) Q3 2022 Earnings Conference Call June 10, 2022 8:30 AM ET Company Participants Chris Calabrese - Investor Relations Hamid Erfanian - Chief Executive Officer David Bench - Chief Financial Officer Conference Call Participants J. P. Sullivan - Potomac Capital Presentatio...
News, Short Squeeze, Breakout and More Instantly...
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights The Company's Life Science division's...
FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fis...